Trials / Completed
CompletedNCT00892281
ORCA - Oracea® for Rosacea: A Community-based Assessment
A Phase 4, Open-Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With Oracea® [Doxycycline, USP] Capsules 40 mg (30 mg Immediate Release & 10 mg Delayed Release Beads) When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,421 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | doxycycline (Oracea®) 40 mg modified release as monotherapy | Take once daily in the morning |
| DRUG | doxycycline (Oracea®) 40 mg modified release as add-on therapy | Take once daily in the morning |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2009-05-04
- Last updated
- 2022-08-25
- Results posted
- 2010-11-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00892281. Inclusion in this directory is not an endorsement.